Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Metastatic Steroid-cell Tumor of the Ovary
NCT06328491Completed
- Sponsor
- University Health Network
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of erdafitinib in Steroid Cell Tumor of the Ovary (SCT), sponsored by University Health Network. Primary endpoints: Tumor response at 3 months and Overall health status at 3 months. Started May 2022; status: completed.
02
Drugs
erdafitinib
03
Conditions
Steroid Cell Tumor of the Ovary (SCT)
Beyond the preview
Go deeper on NCT06328491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06328491.